

Talking to your healthcare team

What to ask to get the information you need

Whether you have specific questions about starting treatment with SARCLISA or more general questions about your overall health and well-being, your healthcare team is your best resource for the information you need.

Below are some tips to help you make the most out of your next appointment.



Prepare for your call or visit by deciding which questions you want to ask



Take notes during your call or visit to help you keep track of the answers you receive



Bring a caregiver or companion for support and to be an extra set of ears

On the following pages, you'll find examples of questions to ask your doctor, nurse, or pharmacist. Use the spaces provided to write down answers or add your own questions and notes.

Considering SARCLISA?

Use the questions suggested on page 5 to help start the conversation with your doctor.

What is SARCLISA?

SARCLISA is a prescription medicine used in combination with:

- The medicines pomalidomide and dexamethasone, to treat adults who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor to treat multiple myeloma.
- The medicines carfilzomib and dexamethasone, to treat adults with multiple myeloma who have already received 1 to 3 lines of treatment and they did not work or are no longer working.
- The medicines bortezomib, lenalidomide and dexamethasone, to treat adults with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant).

It is not known if SARCLISA is safe and effective in children.

Important Safety Information

Do not receive SARCLISA if you have a severe allergic reaction to isatuximab-irfc or any of the ingredients in SARCLISA (see the list of ingredients in the full [Prescribing Information](#)).

Please see additional Important Safety Information on pages 6 and 7, and accompanying full [Prescribing Information](#), including [Patient Information](#).



My infusion appointments

Questions for my healthcare team

- How often will I receive infusions of SARCLISA?
- How long will my infusion appointments be?
- What should I do to prepare for my infusion appointments?
- Can I bring anything to do to pass the time during the appointment?
- Can I drive myself home after an infusion appointment?
- If I need transportation assistance, what options are available?
- What should I do if I miss an infusion appointment?

Responses

Don't hesitate to ask for information or explanations about anything you don't understand or want to understand better.



My treatment

Questions for my healthcare team

- What side effects should I be aware of?
- How should I manage side effects if I experience any?
- Can you explain how SARCLISA works to treat multiple myeloma?
- How will I know if my treatment is working?
- What follow-up lab tests will I need?
- What test results should I keep track of?
- Can you help me understand my test results?
- What do I need to know about the other medicines that are given together with SARCLISA?
- Can the other medicines and supplements I take affect my treatment with SARCLISA?
- Who else is on my healthcare team, and what information can they offer me?
- Does your office/hospital/infusion center offer resources that may help me?

Responses


Please see additional Important Safety Information on pages 6 and 7, and accompanying full Prescribing Information, including Patient Information.




Questions for my healthcare team

- Are there changes I should consider making to my lifestyle that could improve my treatment experience?
- What can I do if I experience symptoms related to my multiple myeloma?
- Are there specific dietary changes I should consider?
- What kind of exercise could help me feel my best during treatment?
- Can I continue to work while receiving treatment?
- Are there concerns I should be aware of if I travel while receiving treatment?
- Could any of the medicines I'm receiving affect my emotional health?
- Is there support available for me if the medicines I'm receiving affect my emotional health?

Responses



SARCLISA.com
Visit our website to find more helpful resources



Scan with your smartphone camera

Questions for my doctor

Consider asking these questions at your next appointment to find out if SARCLISA is right for you.

- Based on my treatment history, is SARCLISA an option for me?
- Can you tell me how SARCLISA works?
- How could treatment with SARCLISA help me?
- What were the study results for SARCLISA?
- What are the possible side effects of treatment?
- What is the treatment schedule for SARCLISA?
- Is there a patient support program that may help with the cost of SARCLISA?

Responses

Please see additional Important Safety Information on pages 6 and 7, and accompanying full Prescribing Information, including Patient Information.



Important Safety Information (Cont'd)

Before receiving SARCLISA, tell your healthcare provider about all of your medical conditions, including if you:

- Have an infection.
- Have heart problems, if your healthcare provider prescribes SARCLISA in combination with carfilzomib and dexamethasone for you.
- Have had shingles (herpes zoster).
- Are pregnant or plan to become pregnant. SARCLISA can harm your unborn baby.
 - Females who are able to become pregnant should use an effective method of birth control during treatment and for 5 months after your last dose of SARCLISA. Talk to your healthcare provider about birth control methods that you can use during this time.
 - Tell your healthcare provider right away if you think you are pregnant or become pregnant during treatment with SARCLISA.
 - Before receiving SARCLISA in combination with either pomalidomide or lenalidomide, females and males must agree to the instructions in the pomalidomide or lenalidomide REMS program. The pomalidomide and lenalidomide REMS program have specific requirements about birth control, pregnancy testing, blood donation, and sperm donation that you need to know. Talk to your healthcare provider to learn more about pomalidomide or lenalidomide.
- Are breastfeeding or plan to breastfeed. It is not known if SARCLISA passes into your breast milk. Do not breastfeed during treatment with SARCLISA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive SARCLISA?

- SARCLISA will be given to you by your healthcare provider by intravenous (IV) infusion into your vein.
- **SARCLISA in combination with pomalidomide and dexamethasone, or SARCLISA in combination with carfilzomib and dexamethasone** is given in treatment cycles of 28 days (4 weeks).
 - Cycle 1 (28-day cycle), SARCLISA is given weekly.
 - Cycle 2 and beyond (28-day cycles), SARCLISA is given every 2 weeks.

- **SARCLISA in combination with bortezomib, lenalidomide, and dexamethasone** is given in treatment cycles of 42 days (6 weeks) from cycle 1 to 4 and in treatment cycles of 28 days (4 weeks) from cycle 5.
 - Cycle 1 (42-day cycle), SARCLISA is given weekly (Days 1, 8, 15, 22, and 29).
 - Cycles 2 to 4 (42-day cycles), SARCLISA is given every 2 weeks (Days 1, 15, and 29).
 - Cycles 5 to 17 (28-day cycles), SARCLISA is given every 2 weeks (Days 1 and 15).
 - Cycles 18 and beyond (28-day cycles), SARCLISA is given every 4 weeks.
- Your healthcare provider will decide how many treatments you will receive.
- Your healthcare provider will give you medicines before each infusion of SARCLISA to help reduce the risk of infusion reactions (make them less frequent and severe).
- If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

What are the possible side effects of SARCLISA?

SARCLISA may cause serious side effects, including:

- **Infusion reactions.** Infusion reactions are common with SARCLISA and can sometimes be severe or life threatening.
 - Your healthcare provider will prescribe medicines before each infusion of SARCLISA to help decrease your risk for infusion reactions or to help make any infusion reaction less severe. You will be monitored for infusion reactions during each infusion of SARCLISA.
 - Your healthcare provider may slow down or stop your infusion, or completely stop treatment with SARCLISA if you have an infusion reaction.

Get medical help right away if you develop any of the following symptoms of infusion reaction during or after an infusion of SARCLISA:

- | | |
|---|------------------------|
| – shortness of breath, wheezing, or trouble breathing | – headache |
| – swelling of the face, mouth, throat, or tongue | – cough |
| – throat tightness | – rash or itching |
| – palpitations | – nausea |
| – dizziness, lightheadedness, or fainting | – runny or stuffy nose |
| | – chills |

- **Infections.** SARCLISA can cause infections that are severe, life-threatening, or that may lead to death. Your healthcare provider will monitor you for signs and symptoms of infection before and during treatment with SARCLISA. Your healthcare provider may prescribe medicines for you to help prevent infections and treat you as needed if you develop an infection during treatment with SARCLISA. **Tell your healthcare provider right away if you develop a fever or any signs or symptoms of infection during treatment with SARCLISA.**

- **Decreased white blood cell counts.** Decreased white blood cell counts are common with SARCLISA and certain white blood cells can be severely decreased. Fever can occur with low white blood cell counts and may be a sign that you have an infection. Your healthcare provider will check your blood cell counts during treatment with SARCLISA and may prescribe a medicine to help increase your white blood cell counts. **Tell your healthcare provider right away if you develop any fever or symptoms of infection during treatment with SARCLISA.**

- **Risk of new cancers.** New cancers have happened in people during and after treatment with SARCLISA. Your healthcare provider will monitor you for new cancers during treatment with SARCLISA.

- **Change in blood tests.** SARCLISA may affect the results of blood tests to match your blood type for about 6 months after your last infusion of SARCLISA. Your healthcare provider will do blood tests to match your blood type before you start treatment with SARCLISA. **Tell all of your healthcare providers that you are being treated with SARCLISA before receiving blood transfusions.**

The most common side effects of SARCLISA in combination with pomalidomide and dexamethasone include:

- upper respiratory tract infection
- lung infection (pneumonia)
- diarrhea
- decreased red blood cell count (anemia)
- decreased platelet count (thrombocytopenia)

The most common side effects of SARCLISA in combination with carfilzomib and dexamethasone include:

- upper respiratory tract infection
- tiredness and weakness
- high blood pressure
- diarrhea
- lung infection (pneumonia)
- trouble breathing

- trouble sleeping
- bronchitis
- cough
- back pain
- decreased red blood cell count (anemia)
- decreased platelet count (thrombocytopenia)

The most common side effects of SARCLISA in combination with bortezomib, lenalidomide and dexamethasone include:

- upper respiratory tract infection
- diarrhea
- tiredness and weakness
- tingling or numbness of the arms or legs
- lung infection (pneumonia)
- muscle or bone pain
- clouding of your eye (cataract)
- constipation
- swelling of the hands, legs, ankles and feet
- rash
- trouble sleeping
- COVID-19
- decreased red blood cell count (anemia)
- decreased platelet count (thrombocytopenia)

Heart failure can happen during treatment with SARCLISA in combination with carfilzomib and dexamethasone. **Tell your healthcare provider right away if you develop any of the following symptoms:**


- trouble breathing
- cough
- swelling of your ankles, feet, or legs

These are not all the possible side effects of SARCLISA. For more information, ask your healthcare provider or pharmacist.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see accompanying full **Prescribing Information**, including **Patient Information**.


SARCLISA[®]
(isatuximab-irfc)
Injection for intravenous use
500 mg/25 mL, 100 mg/5 mL



SARCLISA[®]
(isatuximab-irfc)

Injection for intravenous use
500 mg/25 mL, 100 mg/5 mL



Scan with your
smartphone
camera

New to SARCLISA?

Sign up for updates at SARCLISA.com/get-the-latest.



Already signed up?

Visit SARCLISA.com for information about our patient support program, CareASSIST from Sanofi. You can also call **1-833-WE+CARE** (1-833-930-2273), Mon – Fri, 9 AM – 8 PM ET, or visit SanofiCareAssist.com/sarclisa.

Patient Portrayal

sanofi

©2025 Sanofi. All rights reserved.
SARCLISA, CareASSIST, and Sanofi are registered trademarks of Sanofi or an affiliate.
All the other trademarks above are the property of their respective owners,
who have no affiliation or relationship with Sanofi. MAT-US-2004897-v5.0-02/2025